Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
In development
Reference number: GID-TA11235
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-May 2024 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately late-July 2024.